← Eichor
Study identifier: NCT07306624 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer  ·  Sponsor: STCube, Inc.

PhasePhase 2
Planned participants62
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy

This description comes directly from the study's public registry record.

Talk to the study team

Heeyeon Jung  ·  82-2-551-3370  ·  junghy@stcube.com

Always discuss trial participation with your own doctor first.

Locations (5)

The Catholic University of Korea St. Vincent's HospitalGyeonggi-do, South KoreaRecruiting
Kangbuk Samsung HospitalSeoul, South KoreaRecruiting
Korea University Anam HospitalSeoul, South KoreaRecruiting
Samsung Medical CenterSeoul, South KoreaRecruiting
Seoul National University Bundang HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07306624